
Brightlands Venture Partners
Financial History
Leadership Team
Key people at Brightlands Venture Partners.

Key people at Brightlands Venture Partners.
Key people at Brightlands Venture Partners.
Brightlands Venture Partners (BVP) is a venture capital firm focused on accelerating innovative start-ups that address major environmental and health challenges, particularly in the sectors of Renewable Chemistry & Circularity, HealthTech & Life Sciences, and Agritech & Food. Their mission is to support companies that contribute to sustainability and health by providing growth capital, deep sector expertise, and a vast network, aiming to future-proof industries like chemical, agricultural, and healthcare. BVP invests primarily at seed to Series A stages, emphasizing breakthrough proprietary technology, strong growth ambition, and credible business models, typically with initial investments between €250k and €2M. They actively support portfolio companies with strategic value, co-investor connections, and follow-on funding, maintaining a high-conviction, focused investment approach[1][2][3][4].
Founded in 2004, BVP has evolved through managing four funds totaling around €120 million in committed capital, including Limburg Ventures (€15M, 2004), Chemelot Ventures (€40M, 2014), Brightlands Agrifood Fund (€20M, 2017), and BVP Fund IV (€45M, 2021). The firm was an early adopter of impact investing, embedding sustainability and health impact into its core DNA well before it became mainstream. Their team combines diverse expertise, and their investment philosophy centers on supporting start-ups with game-changing technologies that can scale globally and generate positive societal impact. BVP’s origin in the south of the Netherlands leverages proximity to the Brightlands ecosystem, enhancing portfolio companies' chances of success through close collaboration and network effects[1][3][4][5].
BVP rides the global trend toward sustainability and health innovation, addressing urgent societal challenges like climate change, biodiversity loss, and healthcare accessibility. The timing is critical as technological breakthroughs in renewable chemistry, life sciences, and agritech become essential for transitioning industries toward circularity and sustainability. Market forces such as increasing regulatory pressure, consumer demand for sustainable products, and advances in biotech and materials science favor BVP’s investment focus. By nurturing early-stage ventures with breakthrough technologies, BVP influences the broader ecosystem by accelerating the commercialization of innovations that can reshape traditional sectors and contribute to a healthier planet and population[1][3][6].
Looking ahead, Brightlands Venture Partners is poised to deepen its impact by continuing to fund and scale start-ups that deliver sustainable and health-related innovations. Trends such as the circular economy, precision agriculture, digital health, and advanced materials will likely shape their portfolio evolution. Their influence may grow as they leverage their ecosystem and capital to bridge early-stage innovation with market adoption, potentially expanding beyond Europe. BVP’s commitment to impact investing and strategic support positions them well to remain a key player in driving the transition to a sustainable and healthier future[1][3][5].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2025 | Qorium | $25.0M Series A | — | Soffinova Partners |
| May 1, 2025 | Hy2Care | $5.0M Venture Round | — | Jon Moulton |
| Nov 1, 2022 | Circularise | $11.0M Series A | — | Soffinova Partners |
| Sep 1, 2022 | S+dB | $1.0M Seed | — | — |
| Dec 1, 2021 | Verdify | $1.0M Seed | — | — |
| Jul 1, 2021 | Qorium | $3.0M Seed | — | — |
| Nov 1, 2019 | AvL Motion | $1.0M Seed | — | — |
| Apr 1, 2019 | Hy2Care | $4.0M Series A | — | Jon Moulton |
| Dec 1, 2017 | Health Value Creation | $2.0M Series A | — | — |
| Feb 1, 2015 | FABPulous | $2.0M Series B | — | — |
| Feb 1, 2014 | Weedingtech | $1.0M Seed | — | — |
| May 1, 2011 | Q Chip | $6.0M Series C | — | — |